Stero Biotechs

Company Overview

Snapshot

Founded in February 2017, Stero Biotechs operates with 1–10 employees. The company has raised $1 million across one funding round. In January 2021, Stero Biotechs supported an exploratory study for CBD-based treatment for severe COVID-19 patients.

Business overview

Stero Biotechs is a clinical-stage company focused on researching and developing novel treatment solutions that utilize cannabidiol (CBD) to reduce the side effects and need for steroid therapy. The company leverages the immunomodulatory and anti-inflammatory properties of CBD, a non-psychotropic component of cannabis sativa. Stero Biotechs serves the healthcare and life sciences industries, specifically targeting pharmaceutical applications within the medical cannabis sector for conditions such as Crohn's disease, chronic urticaria, and severe COVID-19.

Strategic signal

In January 2021, Stero Biotechs supported an exploratory study for CBD-based treatment in severe COVID-19 patients. This initiative signals the company's agility in addressing urgent global health crises and demonstrates the potential broad applicability of its CBD-based therapeutic approach beyond its initial focus on autoimmune and inflammatory conditions, indicating a strategic expansion of its clinical development pipeline.

Company Intelligence Q&A

What is Stero Biotechs' primary focus?

Stero Biotechs is a clinical-stage company dedicated to researching and developing CBD-based treatment solutions aimed at reducing the side effects and necessity of steroid therapy.

When did Stero Biotechs secure a patent for CBD as a steroid-sparing treatment?

In August 2018, Stero Biotechs secured a patent for CBD as a steroid-sparing treatment, which is expected to allow for significant dosage reduction in patients.

What clinical trials did Stero Biotechs commence in 2020?

Stero Biotechs commenced phase 2a clinical trials for steroid-dependent Crohn's disease in Q1 2020 and for chronic urticaria in Q3 2020.

What was the outcome of the proposed acquisition by Kalytera?

In April 2020, Kalytera and Stero Biotechs announced that they would not proceed with the previously planned acquisition.

What was Stero Biotechs' involvement in COVID-19 treatment research?

In January 2021, Stero Biotechs supported an exploratory study for CBD-based treatment for severe COVID-19 patients, following an announcement in April 2020 about an IP-protected clinical trial for COVID-19 patients using a CBD-steroid treatment.